Abstract
Abnormalities in microRNA expression in tumor cells are widely used as a basis to develop novel therapeutic and diagnostic approaches in oncology. The former mostly aims to target oncogenic microRNAs or to restore expression of microRNAs with tumor suppressor properties in cancer cells. However recently another way of using specific microRNA loss in tumor cells has been suggested. The strategy relies on frequently lost in cancer cells but abundant in cell of normal tissues specific microRNAs, and aims to control unwanted expression of a gene essential for therapeutic action, either therapeutic transgene or essential for viral replication gene in oncolytic viruses, thus minimizing damage to normal tissues and improving safety of cancer gene therapy. Here, history of development and basic principles of the approach as well as current progress in the field are overviewed, with emphasis on benefits brought by the microRNA-based control of specificity for cancer gene therapy and emerging possibility of personification of treatment.
Current Cancer Therapy Reviews
Title:MicroRNAs in Cancer Gene Therapy: Another Look
Volume: 10 Issue: 3
Author(s): Igor V. Korobko
Affiliation:
Keywords: Cancer gene therapy; microRNA; tumor specificity.
Abstract: Abnormalities in microRNA expression in tumor cells are widely used as a basis to develop novel therapeutic and diagnostic approaches in oncology. The former mostly aims to target oncogenic microRNAs or to restore expression of microRNAs with tumor suppressor properties in cancer cells. However recently another way of using specific microRNA loss in tumor cells has been suggested. The strategy relies on frequently lost in cancer cells but abundant in cell of normal tissues specific microRNAs, and aims to control unwanted expression of a gene essential for therapeutic action, either therapeutic transgene or essential for viral replication gene in oncolytic viruses, thus minimizing damage to normal tissues and improving safety of cancer gene therapy. Here, history of development and basic principles of the approach as well as current progress in the field are overviewed, with emphasis on benefits brought by the microRNA-based control of specificity for cancer gene therapy and emerging possibility of personification of treatment.
Export Options
About this article
Cite this article as:
V. Korobko Igor, MicroRNAs in Cancer Gene Therapy: Another Look, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/157339471003150212111836
DOI https://dx.doi.org/10.2174/157339471003150212111836 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Current Drug Targets The Alleviating Effect of Herniarin Against Ionizing Radiation-Induced Genotoxicity and Cytotoxicity in Human Peripheral Blood Lymphocytes
Current Radiopharmaceuticals Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Marine Sesterterpenes: An Overview
Current Organic Chemistry EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development
Current Pharmaceutical Design HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Current Topics in Medicinal Chemistry Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Quantum Chemical Studies on Ultimate Carcinogenic Metabolites from Polycyclic Aromatic Hydrocarbons
Current Medicinal Chemistry The Vanilloid Agonist Resiniferatoxin for Interventional-Based Pain Control
Current Topics in Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued)